Efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH (SELECT randomised trial)
SELECT was discontinued for futility, as no treatment effect on the primary end-point (PVR) was observed. Safety data were consistent with the established safety profile of selexipag, with no new safety signals identified.
Authors
- Joanna Pepke‐Żaba (ORCID: https://orcid.org/0000-0003-3764-3563)
- Nick H. Kim (ORCID: https://orcid.org/0000-0003-4702-650X)
- Julian Ilcheff Borissoff
- S. Gesang
- Michael M. Madani (ORCID: https://orcid.org/0000-0001-8056-8007)
- Marion Delcroix (ORCID: https://orcid.org/0000-0001-8394-9809)
- Richard N. Channick (ORCID: https://orcid.org/0000-0002-9016-4468)
- Hossein Ardeschir Ghofrani (ORCID: https://orcid.org/0000-0002-2029-4419)
- Valerie Easton
- Dominik Richard
Institutions
- Royal Papworth Hospital (GB)
- UCLA Health (US)
- UC San Diego Health System (US)
- UCLA Medical Center (US)
- University of California San Diego (US)
- Universities of Giessen and Marburg Lung Center (DE)
- Actelion (Switzerland) (CH)
- KU Leuven (BE)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1183/13993003.00193-2024
- Citations
- 9
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.77
Funders
- Actelion Pharmaceuticals